CHRS · Coherus Oncology Inc. Common Stock
View on chartInsiders & Stakes
| Dennis M. Lanfear President & CEO | ▲ Buy | Grant | 1,048,235 Shares held | 1/23/2026 | View profile |
| Bryan J. McMichael See Remarks | ▲ Buy | Grant | 133,736 Shares held | 1/22/2026 | View profile |
| Vexler Vladimir Chief Scientific Officer | ▼ Sell | Tax Withholding | 116,361 Shares held | 3/31/2023 | View profile |
| Paul Reider Chief Commercial Officer | ▼ Sell | Tax Withholding | 82,069 Shares held | 1/20/2025 | View profile |
| Stilwell McDavid Chief Financial Officer | ▼ Sell | Tax Withholding | 75,305 Shares held | 12/31/2023 | View profile |
| Ali J. Satvat Director | ▲ Buy | Grant | 30,000 Shares held | 6/5/2026 | View profile |
| Rita A. Karachun Sr. VP Fince-Global Controller | ▲ Buy | Grant | 30,000 Shares held | 6/5/2026 | View profile |
| Lee Nisley Newcomer Director | ▲ Buy | Grant | 30,000 Shares held | 6/5/2026 | View profile |
| Michael Lee Ryan | ▲ Buy | Grant | 30,000 Shares held | 6/5/2026 | View profile |
| Jill O'Donnell-Tormey | ▲ Buy | Grant | 30,000 Shares held | 6/5/2026 | View profile |
| Mats Wahlstrom Director | ▲ Buy | Grant | 30,000 Shares held | 6/5/2026 | View profile |
| Charles W. Newton Chief Financial Officer | ▲ Buy | Grant | 30,000 Shares held | 6/5/2026 | View profile |
| James Healy Director | ▼ Sell | Open Market | 0 Shares held | 9/29/2021 | View profile |
Transaction History
| Ali J. Satvat | ▲ Buy | Grant | 30,000 | $0 | 6/5/2026 |
| Rita A. Karachun | ▲ Buy | Grant | 30,000 | $0 | 6/5/2026 |
| Lee Nisley Newcomer | ▲ Buy | Grant | 30,000 | $0 | 6/5/2026 |
| Michael Lee Ryan | ▲ Buy | Grant | 30,000 | $0 | 6/5/2026 |
| Jill O'Donnell-Tormey | ▲ Buy | Grant | 30,000 | $0 | 6/5/2026 |
| Mats Wahlstrom | ▲ Buy | Grant | 30,000 | $0 | 6/5/2026 |
| Charles W. Newton | ▲ Buy | Grant | 30,000 | $0 | 6/5/2026 |
| Dennis M. Lanfear | ▲ Buy | Grant | 375,000 | $0 | 1/23/2026 |
| Bryan J. McMichael | ▲ Buy | Grant | 112,500 | $0 | 1/22/2026 |
| Bryan J. McMichael | ▼ Sell | Tax Withholding | 1,715 | $3K | 1/20/2026 |
| Dennis M. Lanfear | ▼ Sell | Tax Withholding | 11,839 | $18K | 1/20/2026 |
| Mats Wahlstrom | ▼ Sell | Open Market | 99,988 | $74K | 5/23/2025 |
| Bryan J. McMichael | ▼ Sell | Tax Withholding | 1,711 | $2K | 1/20/2025 |
| Paul Reider | ▼ Sell | Tax Withholding | 4,858 | $7K | 1/20/2025 |
| Dennis M. Lanfear | ▼ Sell | Tax Withholding | 11,810 | $16K | 1/20/2025 |
| Bryan J. McMichael | ▼ Sell | Tax Withholding | 1,711 | $3K | 1/7/2025 |
| Dennis M. Lanfear | ▼ Sell | Tax Withholding | 11,810 | $20K | 1/4/2025 |
| Paul Reider | ▼ Sell | Tax Withholding | 2,277 | $4K | 1/4/2025 |
| Paul Reider | ▼ Sell | Tax Withholding | 2,073 | $3K | 12/13/2024 |
| Mats Wahlstrom | ▼ Sell | Gift | 99,988 | $0 | 2/9/2024 |
| Mats Wahlstrom | ▼ Sell | Gift | 99,988 | $0 | 2/9/2024 |
| Mats Wahlstrom | ▲ Buy | Option Exercise | 14,997 | $25K | 2/1/2024 |
| Mats Wahlstrom | ▲ Buy | Option Exercise | 44,991 | $75K | 2/1/2024 |
| Bryan J. McMichael | ▼ Sell | Tax Withholding | 1,707 | $4K | 1/20/2024 |
| Dennis M. Lanfear | ▼ Sell | Tax Withholding | 11,218 | $27K | 1/20/2024 |
| Paul Reider | ▼ Sell | Tax Withholding | 4,854 | $12K | 1/20/2024 |
| Bryan J. McMichael | ▼ Sell | Tax Withholding | 1,707 | $5K | 1/7/2024 |
| Dennis M. Lanfear | ▼ Sell | Tax Withholding | 11,781 | $34K | 1/4/2024 |
| Paul Reider | ▼ Sell | Tax Withholding | 2,275 | $7K | 1/4/2024 |
| Stilwell McDavid | ▼ Sell | Tax Withholding | 18,440 | $61K | 12/31/2023 |
| Paul Reider | ▼ Sell | Tax Withholding | 2,049 | $5K | 12/13/2023 |
| Dennis M. Lanfear | ▲ Buy | Option Exercise | 41,000 | $58K | 11/22/2023 |
| Dennis M. Lanfear | ▲ Buy | Option Exercise | 258,940 | $367K | 11/22/2023 |
| Dennis M. Lanfear | ▼ Sell | Open Market | 223,100 | $450K | 11/22/2023 |
| Paul Reider | ▼ Sell | Tax Withholding | 2,451 | $17K | 4/1/2023 |
| Stilwell McDavid | ▼ Sell | Tax Withholding | 3,457 | $24K | 4/1/2023 |
| Vexler Vladimir | ▼ Sell | Tax Withholding | 16,278 | $111K | 3/31/2023 |
| Dennis M. Lanfear | ▲ Buy | Grant | 86,250 | $0 | 1/20/2023 |
| Bryan J. McMichael | ▲ Buy | Grant | 12,500 | $0 | 1/20/2023 |
| Vexler Vladimir | ▲ Buy | Grant | 40,000 | $0 | 1/20/2023 |
| Stilwell McDavid | ▲ Buy | Grant | 40,000 | $0 | 1/20/2023 |
| Vexler Vladimir | ▼ Sell | Tax Withholding | 3,602 | $37K | 1/11/2023 |
| Vexler Vladimir | ▼ Sell | Tax Withholding | 3,602 | $35K | 1/10/2023 |
| Bryan J. McMichael | ▼ Sell | Tax Withholding | 1,699 | $16K | 1/7/2023 |
| Dennis M. Lanfear | ▼ Sell | Tax Withholding | 10,905 | $108K | 1/4/2023 |
| Vexler Vladimir | ▼ Sell | Tax Withholding | 5,437 | $54K | 1/4/2023 |
| Stilwell McDavid | ▼ Sell | Tax Withholding | 5,437 | $54K | 1/4/2023 |
| Dennis M. Lanfear | ▼ Sell | Gift | 4,000 | $0 | 12/30/2022 |
| Stilwell McDavid | ▼ Sell | Tax Withholding | 3,458 | $44K | 4/1/2022 |
| Vexler Vladimir | ▼ Sell | Tax Withholding | 3,458 | $44K | 4/1/2022 |
| Mats Wahlstrom | ▲ Buy | Grant | 29,994 | $63K | 2/28/2022 |
| Mats Wahlstrom | ▲ Buy | Grant | 10,006 | $116K | 2/25/2022 |
| Vexler Vladimir | ▼ Sell | Tax Withholding | 3,583 | $51K | 1/11/2022 |
| Vexler Vladimir | ▼ Sell | Tax Withholding | 4,150 | $59K | 1/10/2022 |
| Stilwell McDavid | ▲ Buy | Grant | 40,000 | $0 | 1/4/2022 |
| Dennis M. Lanfear | ▲ Buy | Grant | 86,250 | $0 | 1/4/2022 |
| Vexler Vladimir | ▲ Buy | Grant | 40,000 | $0 | 1/4/2022 |
| Dennis M. Lanfear | ▼ Sell | Gift | 10,000 | $0 | 11/17/2021 |
| Stilwell McDavid | ▼ Sell | Open Market | 3,507 | $59K | 10/15/2021 |
| James Healy | ▼ Sell | Open Market | 286,076 | $4.6M | 9/29/2021 |
| James Healy | ▼ Sell | Open Market | 48,329 | $830K | 9/28/2021 |
| James Healy | ▼ Sell | Open Market | 100,150 | $1.8M | 9/27/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
CHRS Retains Oppenheimer to Market Legacy Biosimilar Assets
Coherus Oncology announced that it has retained Oppenheimer & Co. to market its legacy biosimilar assets. The move aims to increase visibility and potential partnerships for older products in its pipeline. The stock is currently near a long‑standing support level, which may draw attention as the company pursues these marketing efforts.
CHRS Retains Oppenheimer to Market Legacy Biosimilar Assets. Coherus Oncology announced that it has retained Oppenheimer & Co. to market its legacy biosimilar assets. The move aims to increase visibility and potential partnerships for older products in its pipeline. The stock is currently near a long‑standing support level, which may draw attention as the company pursues these marketing efforts.